Braun Stacey Associates Inc. lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 20,516 shares of the biopharmaceutical company's stock after selling 976 shares during the quarter. Braun Stacey Associates Inc.'s holdings in Regeneron Pharmaceuticals were worth $13,012,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Pinney & Scofield Inc. bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares in the last quarter. OFI Invest Asset Management bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. lifted its stake in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares in the last quarter. Finally, Tompkins Financial Corp bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth $32,000. Institutional investors own 83.31% of the company's stock.
Regeneron Pharmaceuticals Stock Performance
Shares of REGN traded up $9.64 during trading hours on Tuesday, hitting $547.75. The company had a trading volume of 847,049 shares, compared to its average volume of 909,523. The firm has a market cap of $59.14 billion, a price-to-earnings ratio of 13.94, a PEG ratio of 1.98 and a beta of 0.33. The business has a fifty day moving average of $547.51 and a 200-day moving average of $623.07. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. During the same period in the previous year, the company earned $9.55 earnings per share. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% compared to the same quarter last year. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.
Regeneron Pharmaceuticals Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.64%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.
Wall Street Analyst Weigh In
REGN has been the topic of a number of research reports. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price objective on the stock. Royal Bank Of Canada lowered shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective on the stock. in a research report on Friday, May 30th. Robert W. Baird cut their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday, April 25th. Finally, Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $822.58.
Check Out Our Latest Analysis on REGN
About Regeneron Pharmaceuticals
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Further Reading
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
